Aurobindo Pharma Q3 Review - Product Mix To Shift Towards Injectable, Specialty: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We are positive on Aurobindo Pharma Ltd. and we upgrade our rating based on guidance of -
- better product mix with higher contribution of injectable exports as guided to be $650-700 million in FY23E versus $380 million in FY20,
- Eugia (Oncology) product launch in U.S. and Europe with 52 products under development stage at present,
- Europe Ebitdam to cross 20% plus in FY23 from current 15%,
- better outlook on Auromedics for next two quarters and
- divestment of Natrol.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.